Brief: INmune Bio Announces Expansion Of Phase II Clinical Trial For Alzheimer’S Disease In Europe
15/11/2023 15:01
Nov 15 (Reuters) - INmune Bio Inc INMB.O :
* INMUNE BIO INC. ANNOUNCES EXPANSION OF PHASE II CLINICAL
TRIAL
FOR ALZHEIMER’S DISEASE IN EUROPE
* INMUNE BIO INC: ALSO RECENTLY RECEIVED A CASH REFUND OF
ABOUT
$2.8 MILLION PURSUANT TO A RESEARCH AND DEVELOPMENT TAX
INCENTIVE FROM AUSTRALIA
Source text for Eikon: ID:nGNXNXZyH
Further company coverage: INMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview